An Open Label, Non-Interventional Study of the Safety of Desvenlafaxine Succinate (Pristiq) in the Treatment of Major Depressive Disorder (MDD) and Vasomotor Symptoms (VMS) Associated With Menopause in Filipino Adult Patients: a Post Marketing Surveillance Study.

Trial Profile

An Open Label, Non-Interventional Study of the Safety of Desvenlafaxine Succinate (Pristiq) in the Treatment of Major Depressive Disorder (MDD) and Vasomotor Symptoms (VMS) Associated With Menopause in Filipino Adult Patients: a Post Marketing Surveillance Study.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder; Vasomotor symptoms
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 15 Jan 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 16 Jun 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2014 to 1 Nov 2014.
    • 19 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2014 to 1 May 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top